Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Open Orphan Plc ( (GB:HVO) ) is now available.
hVIVO plc will host a Capital Markets Day in London on 11 June 2026 to showcase its transition from a specialist human challenge trial provider to an integrated, full-service early clinical development platform. The event targets analysts, institutional investors and media, and will highlight how hVIVO supports biopharma clients from preclinical strategy through first-in-human and patient trials using its end-to-end capabilities.
Presentations from clients, investors and industry experts, including representatives from Boehringer Ingelheim, RA Capital, ILiAD Biotechnologies and Decoy Therapeutics, will examine the strategic value of human challenge trials and specialist partners in early drug development. Case studies, such as hVIVO’s work on Cidara Therapeutics’ programme and the world’s first Phase III pivotal human challenge trial, aim to demonstrate how its model can accelerate timelines, improve data quality and reduce execution risk, underscoring its bid to strengthen industry positioning and investor confidence.
Attendees will also hear discussion of emerging investment trends in infectious disease and how integrated platforms like hVIVO’s can support faster, more informed development decisions across Big Pharma and biotech. The programme concludes with tours of hVIVO’s Canary Wharf quarantine facility and laboratories, reinforcing the company’s operational scale and capabilities for stakeholders unable to access on-site services regularly.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on HVO Stock
According to Spark, TipRanks’ AI Analyst, HVO is a Neutral.
The score is held back primarily by the latest financial deterioration (losses, negative gross profit, and significant cash flow weakness). Offsetting this are moderately positive technical momentum signals and earnings-call indications of improving demand/pipeline, though liquidity and booking visibility remain key near-term risks.
To see Spark’s full report on HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. Its end-to-end platform spans preclinical strategy, first-in-human studies, Phase II patient trials and specialist virology and immunology laboratory services, delivered via owned facilities and a large participant database in the UK and Germany.
The group, with more than a century of combined heritage, operates four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials and Laboratories. These offerings are designed to accelerate clinical proof-of-concept, using its London quarantine facility, Phase I/II CRO and Phase II/III site services, and Europe’s largest specialist recruitment database to help clients generate fast, controlled, high-quality data.
Average Trading Volume: 3,067,230
Technical Sentiment Signal: Sell
Current Market Cap: £51.63M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.